|
1
|
Bansal N, Herzog TJ, Shaw RE, Burke WM,
Deutsch I and Wright JD: Primary therapy for early-stage cervical
cancer: Radical hysterectomy vs radiation. Am J Obstet Gynecol.
201:485.e1–485.e9. 2009. View Article : Google Scholar
|
|
2
|
Kosmas C, Mylonakis N, Tsakonas G, Vorgias
G, Karvounis N, Tsavaris N, Daladimos T, Kalinoglou N, Malamos N,
Akrivos T, et al: Evaluation of the paclitaxel-ifosfamide-cisplatin
(TIP) combination in relapsed and/or metastatic cervical cancer. Br
J Cancer. 101:1059–1065. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang SL, Wang YS, Zhou T, Yu XW, Wei ZT
and Li YL: Isolation and characterization of cancer stem cells from
cervical cancer HeLa cells. Cytotechnology. 64:477–484. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bapat SA, Mali AM, Koppikar CB and Kurrey
NK: Stem and progenitor-like cells contribute to the aggressive
behavior of human epithelial ovarian cancer. Cancer Res.
65:3025–3029. 2005.PubMed/NCBI
|
|
5
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olempska M, Eisenach PA, Ammerpohl O,
Ungefroren H, Fandrich F and Kalthoff H: Detection of tumor stem
cell markers in pancreatic carcinoma cell lines. Hepatobiliary
Pancreat Dis Int. 6:92–97. 2007.PubMed/NCBI
|
|
7
|
Tu SM, Lin SH and Logothetis CJ: Stem-cell
origin of metastasis and heterogeneity in solid tumours. Lancet
Oncol. 3:508–513. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Szotek PP, Pieretti-Vanmarcke R, Masiakos
PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F,
Maclaughlin DT and Donahoe PK: Ovarian cancer side population
defines cells with stem cell-like characteristics and Mullerian
inhibiting substance responsiveness. Proc Natl Acad Sci USA.
103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goodell MA, Brose K, Paradis G, Conner AS
and Mulligan RC: Isolation and functional properties of murine
hematopoietic stem cells that are replicating in vivo. J Exp Med.
183:1797–1806. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou S, Schuetz JD, Bunting KD, Colapietro
AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M,
Nakauchi H, et al: The ABC transporter Bcrp1/ABCG2 is expressed in
a wide variety of stem cells and is a molecular determinant of the
side-population phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirschmann-Jax C, Foster AE, Wulf GG,
Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK: A distinct
'side population' of cells with high drug efflux capacity in human
tumor cells. Proc Natl Acad Sci USA. 101:14228–14233. 2004.
View Article : Google Scholar
|
|
13
|
Wulf GG, Wang RY, Kuehnle I, Weidner D,
Marini F, Brenner MK, Andreeff M and Goodell MA: A leukemic stem
cell with intrinsic drug efflux capacity in acute myeloid leukemia.
Blood. 98:1166–1173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qin Zl, Zheng XX and Xu YH: Increased
angiogenesis and decreased programmed cell death increases the risk
of uterine cervical cancer. Drug Res. Oct 21–2014.Epub ahead of
print.
|
|
15
|
Yang B, Ma YF and Liu Y: Elevated
expression of Nrf-2 and ABCG2 involved in multi-drug resistance of
lung cancer SP cells. Drug Res. Nov 4–2014.Epub ahead of print.
|
|
16
|
Zhang QH, Dou HT, Xu P, Zhuang SC and Liu
PS: Tumor recurrence and drug resistance properties of side
population cells in high grade ovary cancer. Drug Res. 65:153–157.
2015.
|
|
17
|
Shi Y, Fu X, Hua Y, Han Y, Lu Y and Wang
J: The side population in human lung cancer cell line NCI-H460 is
enriched in stem-like cancer cells. PLoS One. 7:e333582012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan J, Li R, Zhang R, Liu HL, Zhang N,
Zhang FQ and Dou KF: effect of Bcl-2 and Bax on survival of side
population cells from hepatocellular carcinoma cells. World J
Gastroenterol. 13:6053–6059. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park JR, Kim RJ, Lee YK, Kim SR, Roh KJ,
Oh SH, Kong G, Kang KS and Nam JS: Dysadherin can enhance
tumorigenesis by conferring properties of stem-like cells to
hepatocellular carcinoma cells. J Hepatol. 54:122–131. 2011.
View Article : Google Scholar
|
|
20
|
Shimamura T, Yasuda J, Ino Y, Gotoh M,
Tsuchiya A, Nakajima A, Sakamoto M, Kanai Y and Hirohashi S:
Dysadherin expression facilitates cell motility and metastatic
potential of human pancreatic cancer cells. Cancer Res.
64:6989–6995. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim RJ, Kim SR, Roh KJ, Park SB, Park JR,
Kang KS, Kong G, Tang B, Yang YA, Kohn EA, et al: Ras activation
contributes to the maintenance and expansion of Sca-1pos
cells in a mouse model of breast cancer. Cancer Lett. 287:172–181.
2010. View Article : Google Scholar
|
|
22
|
Singh A, Wu H, Zhang P, Happel C, Ma J and
Biswal S: expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer
cells that confers side population and chemoresistance phenotype.
Mol Cancer Ther. 9:2365–2376. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and
Dick JE: A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature. 367:645–648. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hass R, Giese G, Meyer G, Hartmann A, Dörk
T, Köhler L, Resch K, Traub P and Goppelt-Strübe M: Differentiation
and retrodifferentiation of U937 cells: Reversible induction and
suppression of intermediate filament protein synthesis. Eur J Cell
Biol. 51:265–271. 1990.PubMed/NCBI
|
|
27
|
Salnikov AV, Gladkich J, Moldenhauer G,
Volm M, Mattern J and Herr I: CD133 is indicative for a resistance
phenotype but does not represent a prognostic marker for survival
of non-small cell lung cancer patients. Int J Cancer. 126:950–958.
2010.
|
|
28
|
Itoh K, Chiba T, Takahashi S, Ishii T,
Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et
al: An Nrf2/small Maf heterodimer mediates the induction of phase
II detoxifying enzyme genes through antioxidant response elements.
Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K,
Yamamoto M, Talalay P and Kensler TW: Sensitivity to carcinogenesis
is increased and chemoprotective efficacy of enzyme inducers is
lost in nrf2 transcription factor-deficient mice. Proc Natl Acad
Sci USA. 98:3410–3415. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kwak MK, Kensler TW and Casero RA Jr:
Induction of phase 2 enzymes by serum oxidized polyamines through
activation of Nrf2: effect of the polyamine metabolite acrolein.
Biochem Biophys Res Commun. 305:662–670. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kobayashi A, Kang MI, Okawa H, Ohtsuji M,
Zenke Y, Chiba T, Igarashi K and Yamamoto M: Oxidative stress
sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to
regulate proteasomal degradation of Nrf2. Mol Cell Biol.
24:7130–7139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang DD, Lo SC, Cross JV, Templeton DJ
and Hannink M: Keap1 is a redox-regulated substrate adaptor protein
for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol.
24:10941–10953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Singh A, Misra V, Thimmulappa RK, Lee H,
Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E,
et al: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung
cancer. PLoS Med. 3:e4202006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shibata T, Ohta T, Tong KI, Kokubu A,
Odogawa R, Tsuta K, Asamura H, Yamamoto M and Hirohashi S: Cancer
related mutations in NRF2 impair its recognition by Keap1-Cul3 E3
ligase and promote malignancy. Proc Natl Acad Sci USA.
105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
|
